Final Words: Aligning Innovation, Guidelines, and Access

EP: 1.KMT2A AML Pathogenesis and Presentation

EP: 2.Prognosis and Perception of KMT2A AML

EP: 3.Patient Profiles: Demographics and Disease Biology

EP: 4.Targeting Menin: A New Frontier in AML

EP: 5.Efficacy, Safety, and Experience With Revumenib

EP: 6.Shifts in Standard of Care for Adults and Children With KMT2A AML

EP: 7.Emerging Menin Inhibitors and Patient Impact

EP: 8.Educating on Menin Inhibitors

EP: 9.The Why and When of Molecular Testing in AML

EP: 10.Delays in Detection and the Impact on Access to Targeted Therapy

EP: 11.Accessing Innovation: Practical Tips and Policy Hurdles

EP: 12.The Power of Advocacy: Supporting Patients with KMT2A AML

Now Viewing

EP: 13.Final Words: Aligning Innovation, Guidelines, and Access

This discussion highlighted a sense of optimism mixed with a recognition that there is still much to be done in understanding and treating high-risk AML. Although recent advances provide hope, ongoing research and improved communication remain crucial. Collaboration not only within teams but also between different institutions and between community and academic centers is essential to drive progress and ensure that innovations reach all patients effectively.

The conversation emphasized that treatment should be highly personalized, relying on detailed molecular data from the outset. There is a shared aspiration to cure more patients regardless of age, challenging traditional limitations and encouraging more ambitious goals. Success in this area depends heavily on strengthening partnerships between community health care providers and academic centers, ensuring that patients receive the right therapy at the right time. This personalized approach, combined with expanding therapeutic options, paints a bright outlook for patient outcomes.

Finally, the discussion reflected excitement about the rapid evolution in oncology from broad, nonspecific treatments to targeted therapies based on genetic and epigenetic insights. Educating patients, payers, and health care professionals about how these modern treatments work is critical to advancing care and achieving long-term goals such as cures. The collaborative environment fostered by sharing best practices across institutions and learning from each other’s experiences will continue to propel the field forward, making this a promising era for AML treatment and patient care.